TY - JOUR
T1 - Tissue factor pathway inhibitor endocytosis
AU - Schwartz, Alan L.
AU - Broze, George J.
N1 - Funding Information:
The authors have been supported by grants from National Institutes of Health and Monsanto Corporation.
PY - 1997/10
Y1 - 1997/10
N2 - Tissue factor pathway inhibitor (TFPI), a 42 kD protein, provides the physiological inhibition of tissue factor initiated coagulation by inhibition of both factor Xa and factor VIIa/tissue factor. In plasma, most TFPI is lipoprotein bound with an additional 'releasable' pool bound to the endothelial cell surface. TFPI clearance is via receptor mediated endocytosis into liver. Heparin sulfate proteoglycans and LRP (low density lipoprotein receptor-related protein), an extremely large (~600 kD) cell surface protein, primarily mediate this clearance, although additional TFPI binding sites and endocytosis pathways exist.
AB - Tissue factor pathway inhibitor (TFPI), a 42 kD protein, provides the physiological inhibition of tissue factor initiated coagulation by inhibition of both factor Xa and factor VIIa/tissue factor. In plasma, most TFPI is lipoprotein bound with an additional 'releasable' pool bound to the endothelial cell surface. TFPI clearance is via receptor mediated endocytosis into liver. Heparin sulfate proteoglycans and LRP (low density lipoprotein receptor-related protein), an extremely large (~600 kD) cell surface protein, primarily mediate this clearance, although additional TFPI binding sites and endocytosis pathways exist.
UR - http://www.scopus.com/inward/record.url?scp=0030705207&partnerID=8YFLogxK
U2 - 10.1016/S1050-1738(97)00083-2
DO - 10.1016/S1050-1738(97)00083-2
M3 - Review article
C2 - 21235890
AN - SCOPUS:0030705207
SN - 1050-1738
VL - 7
SP - 234
EP - 239
JO - Trends in Cardiovascular Medicine
JF - Trends in Cardiovascular Medicine
IS - 7
ER -